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ABSTRACT:
Survival of colorectal cancer patients is strongly dependent on development 
of distant metastases. S100A4 is a prognostic biomarker and inducer for colorectal 
cancer metastasis. Besides exerting intracellular functions, S100A4 is secreted 
extracellularly. The receptor for advanced glycation end products (RAGE) is one 
of its interaction partners. The impact of the S100A4-RAGE interaction for cell 
motility and metastasis formation in colorectal cancer has not been elucidated so 
far. Here we demonstrate the RAGE-dependent increase in migratory and invasive 
capabilities of colorectal cancer cells via binding to extracellular S100A4. We show 
the direct interaction of S100A4 and RAGE, leading to hyperactivated MAPK/ERK and 
hypoxia signaling. The S100A4-RAGE axis  increased cell migration (P<0.005) and 
invasion (P<0.005), which was counteracted with recombinant soluble RAGE and 
RAGE-specific antibodies. In colorectal cancer patients, not distantly metastasized 
at surgery, high RAGE expression in primary tumors correlated with metachronous 
metastasis, reduced overall (P=0.022) and metastasis-free survival (P=0.021).
In summary, interaction of S100A4-RAGE mediates S100A4-induced colorectal 
cancer cell motility. RAGE by itself represents a biomarker for prognosis of colorectal 
cancer. Thus, therapeutic approaches targeting RAGE or intervening in S100A4-RAGE-
dependent signaling early in tumor progression might represent alternative strategies 
restricting S100A4-induced colorectal cancer metastasis.
INTRODUCTION
Colorectal cancer (CRC) is the third most common 
type of cancer worldwide, with more than 1.2 million 
new cases and over 600,000 deaths in the year 2008 [1]. 
The major cause for the high mortality of this disease is 
the formation of distant metastases. Patients diagnosed 
with CRC at an early stage have a 5‑year‑survival rate of 
about 90%, which is lowered to 65% by occurring regional 
lymph node metastases, and drops to less than 10% if the 
patient is diagnosed with distant metastases [2].
The small Ca2+ binding protein S100A4 has been 
reported to be highly expressed in different cancer tissues 
(reviewed in [3]). High S100A4 expression in tumors 
correlates with increased metastasis formation [4], 
which has also been shown for CRC [5,6]. In turn, the 
reduction of S100A4 expression in CRC‑xenografted mice 
decreased the occurrence of metastases [7,8]. S100A4 can 
drive metastasis formation in several ways. Intracellular 
interactions with components of the cytoskeleton, as 
well as tumor suppressing proteins modulate the motility 
of cancer cells [9,10]. Additionally, the occurrence 
Oncotarget3221www.impactjournals.com/oncotarget
of S100A4 in the tumor‑stroma microenvironment 
aggravates metastasis formation, partially by remodeling 
the extracellular matrix or the recruitment of factors of the 
immune system [11–13].
The receptor of advanced glycation end 
products (RAGE) is an interaction partner of extracellular 
S100A4 [14]. RAGE is a single membrane spanning 
protein of the immunoglobulin superfamily. Although the 
basal expression of RAGE is low in most tissue types, it 
can be up‑regulated as a cellular response to pathogenic 
environments such as inflammatory conditions [15,16]. 
Systemic inflammation in the intestinal tract, caused e.g. 
by obesity or type 2 diabetes, is counted among the risk 
factors for the development of CRC [17]. The effect of 
RAGE expression on the progression of CRC has been 
shown in murine CRC models [18,19]. Indirect evidence 
of an elevated risk of CRC caused by RAGE‑mediated 
signaling has been provided by epidemiological studies, 
focused on soluble RAGE (sRAGE) levels in CRC 
patients [20,21].
In this study we addressed the impact of a potential 
S100A4‑RAGE interaction for mediating S100A4‑
induced cell motility and metastasis formation of CRC. 
Here we demonstrate the RAGE‑dependent increase 
in the metastatic potential of CRC cells via binding to 
extracellular S100A4. We show the direct interaction of 
RAGE and rS100A4, leading to hyperactivation of the 
mitogen activated protein kinase (MAPK)/ extracellular 
signal‑regulated kinase (ERK) pathway and of the hypoxia 
signaling pathway. Increased cellular motility of RAGE‑
overexpressing cells upon treatment with extracellular 
human recombinant S100A4 (rS100A4) protein could 
be reversed by RAGE‑antagonists, like recombinant 
sRAGE (rsRAGE) and RAGE-specific antibodies. In 
CRC patients, high RAGE expression in primary tumors 
correlated with metastasis formation, as well as with 
shorter metastasis‑free and overall survival.
RESULTS
Direct interaction of S100A4 and RAGE leads to 
enhanced cellular motility in CRC cell lines
We first addressed the interaction of recombinant 
S100A4 and RAGE in CRC cells. Therefore, we analyzed 
the RAGE expression in 10 CRC cell lines (Fig. 1A). 
In order to isolate the impact of RAGE in response to 
rS100A4, and to mimic the up‑regulation of RAGE in 
cancer tissue, we ectopically overexpressed RAGE in 
HCT116, SW620 and DLD‑1 cells.HCT116/RAGE cells 
showed a 12‑fold increase of RAGE mRNA expression, 
compared to the control cell lines HCT116 and HCT116/
vector. RAGE overexpression was confirmed at the 
protein level by Western blotting (Fig. 1B) and by 
immunocytochemistry of RAGE in the cells (Fig. 1C).
We analyzed the receptor‑ligand binding in vitro 
by precipitating RAGE with S100A4‑coupled magnetic 
beads in HCT116/RAGE cells. We demonstrated clearly 
the presence of RAGE in the eluate fraction after the 
pull‑down and thereby the physical interaction of S100A4 
and RAGE. This interaction disappeared by pre‑incubation 
of the lysate with a RAGE-specific antibody (Fig. 1D).
Upon ligand binding, cells can release soluble forms 
of RAGE in the intercellular space which then act as 
soluble decoy receptors by competing with binding of 
ligands [22]. We measured the amount of sRAGE in 
the medium of the cells via RAGE-specific ELISA, 
recognizing N‑terminal RAGE fragments. The ectopic 
overexpression of RAGE in HCT116/RAGE cells alone 
was not sufficient to release elevated amounts of sRAGE. 
However, when we stimulated the HCT116/RAGE with 
rS100A4 we found a significant accumulation of sRAGE 
in the medium, compared to untreated HCT116 and 
HCT116/vector cells (Fig. 1E).
After demonstrating the direct S100A4‑RAGE 
interaction and a cellular response by releasing sRAGE 
following rS100A4 treatment, we determined the impact 
of RAGE activation by extracellular S100A4 for the 
metastatic potential of the cells. Remarkably, the number 
of migrated HCT116/RAGE cells significantly increased 
upon treatment with rS100A4 (Fig. 1F). This increase 
in migration could be counteracted by pre‑incubation 
with rsRAGE. The excess of rsRAGE captures rS100A4 
molecules and restricts the activation of cellular RAGE 
at the plasma membrane. Furthermore, treatment of the 
HCT116/RAGE cells with a RAGE-specific antibody 
prevented RAGE activation by intervening in the S100A4 
binding, thereby counteracting the induction of cell 
migration (Fig. 1F). RAGE overexpression in HCT116/
RAGE cells alone, without rS100A4 treatment, was not 
sufficient to induce cell migration in cell culture. Likewise, 
treatment of HCT116 and HCT116/vector cells with 
rS100A4 had also no effect on cell migration (Fig. 1F).
The ability of RAGE‑overexpressing cells to 
invade through an additional layer of Matrigel was also 
significantly increased when treated with rS100A4. The 
incubation with rsRAGE or with the RAGE-specific 
antibody also resulted in decreased numbers of invaded 
HCT116/RAGE cells. Again, RAGE overexpression 
in HCT116/RAGE cells alone, without rS100A4 
treatment, or treatment of HCT116 and HCT116/vector 
cells with rS100A4 did not result in modulated invasive 
abilities (Fig. 1G).
Next, we addressed the impact of S100A4‑RAGE 
interaction for proliferation. However, when we incubated 
HCT116/RAGE cells with rS100A4, we did not see any 
significant effect on cellular growth, compared to the 
untreated parental HCT116 or to HCT116/vector cells, as 
shown by the doubling time for each subline (Fig. 1H). 
Application of rS100A4 did not significantly change 
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Fig 1: S100A4-RAGE interaction leads to release of sRAGE and increased cellular motility of the CRC cell line 
HCT116. A) RAGE mRNA expression levels in a panel of CRC cell lines, determined by qRT‑PCR. Data represent mean RAGE/
G6PDH mRNA ratios ± SD. Results were normalized to HCT116 cells. B) Generation of HCT116/RAGE cells clones. HCT116 cells 
were transfected with either a RAGE expression plasmid (black bars) or the empty control vector (grey bars). Data represent mean RAGE/
G6PDH mRNA ratios ± SD. Results were normalized to untreated HCT116 cells. For Western blot analyses, equal loading was confirmed 
by GAPDH protein detection. C) Immuncytochemistry staining of HCT116, HCT116/vector, and HCT116/RAGE with RAGE-specific 
antibodies. Nuclei were stained with haematoxylin. D) Interaction of S100A4 and RAGE. Total lysate of HCT116/RAGE cells (lane 1) 
was incubated with magnetic beads, coupled with BSA (lane 2), or human rS100A4 (lanes 3,4). RAGE-specific antibody was added to an 
aliquot of the lysate, prior to bead incubation (lane 4). Bead eluates were blotted and incubated with anti‑RAGE antibodies. E) Release 
of sRAGE upon rS100A4 binding. Supernatants of HCT116, HCT116/vector, and HCT116/RAGE cells were subjected to an ELISA for 
human sRAGE after 24 hours incubation with BSA or rS100A4. The results were normalized to untreated HCT116 cells. Data represent 
mean values ± SD. F,G) Cell migration (F) and cell invasion (G) of HCT116, HCT116/vector, and HCT116/RAGE after treatment with BSA 
or rS100A4. The interaction of S100A4 and RAGE was blocked by supplementing either rsRAGE or RAGE-specific antibody. Numbers 
of migrated and invaded cells were normalized to untreated HCT116 cells, respectively. Data represent mean values ± SD. H) Doubling 
times of HCT116, HCT116/vector and HCT116/RAGE cells were determined by MTT assays. Data represent mean values ± SD. I) S100A4 
mRNA expression levels of HCT116, HCT116/vector, HCT116/RAGE, after treatment with BSA or rS100A4. HCT116/S100A4 cells serve 
as positive control. Data represent mean S100A4/G6PDH mRNA ratios ± SD. Results were normalized to HCT116 cells.
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endogenous S100A4 mRNA expression in HCT116/vector 
and HCT116/RAGE cells, compared to the control cell 
line HCT116 (Fig. 1I).
The increase in cellular motility of RAGE‑
overexpressing cells upon treatment with rS100A4 was 
confirmed in additional CRC cell lines. We generated the 
following SW620‑ as well as DLD‑1‑derived sublines: 
SW620/vector and SW620/RAGE, DLD‑1/vector and 
DLD‑1/RAGE (Fig. 2A,B). Also in SW620/RAGE and 
DLD‑1/RAGE cells, treatment with rS100A4 resulted in a 
significant increase in cell migration (Fig. 2C,D). Again, 
RAGE overexpression in SW620/RAGE and DLD‑1/
RAGE cells alone, without rS100A4 treatment, was not 
sufficient to induce the migration rate, and rS100A4 
treatment of the vector‑transfectants SW620/vector 
and DLD‑1/vector did not lead to elevated numbers of 
migrated cells. Proliferation of SW620 and DLD‑1 cells 
was not affected, neither by RAGE overexpression nor by 
Fig 2: Extracellular rS100A4 increases cellular motility of the CRC cell lines SW620 and DLD-1. A,B) Generation of 
SW620/RAGE and DLD‑1/RAGE cells clones. The CRC cell lines SW620 (A) and DLD‑1 (B) were transfected with either a RAGE 
expression plasmid (black bars) or the empty control vector (grey bars). Data represent mean RAGE/G6PDH mRNA ratios ± SD. Results 
were normalized to each untreated parental cell line (SW620 and DLD‑1, respectively). For Western blot analysis, equal loading was 
confirmed by GAPDH protein detection. C,D) Cell migration of the parental cell lines SW620 (C) and DLD-1 (D), and its derived 
sublines SW620/vector, SW620/RAGE, DLD‑1/vector, DLD‑1/RAGE after treatment with BSA, rS100A4, or with supplemented RAGE‑
specific antibody. Results were normalized to the parental cell lines (SW620 and DLD-1, respectively). Data represent mean values ± SD. 
E,F) Doubling times of the parental cell lines SW620 (E) and DLD‑1 (F), and their derived cell clones expressing the empty vector or 
RAGE were determined by MTT assays. Data represent mean values ± SD.
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incubation with rS100A4 (Fig. 2E,F).
Extracellular S100A4 induces RAGE-mediated 
hyperactivation of MAPK/ERK and hypoxia 
signaling
To identify the signaling pathways involved in 
the RAGE‑dependent increase of cellular motility upon 
rS100A4 treatment, we determined the activity of a panel 
of cancer‑related signaling pathways in HCT116/RAGE 
cells. First we analyzed the basal activity of different 
cancer‑related signaling pathways in untreated HCT116/
vector cells. We observed elevated signal intensities of 
the reporter constructs for MAPK/ERK‑ and MAPK/
JNK-driven transcription, as well as for NFκB- and 
hypoxia‑pathway activities (Fig. 3A). We then normalized 
the pathway‑dependent signals to the untreated HCT116/
vector cells and analyzed the pathways activities in 
RAGE‑overexpressing cells and following treatment with 
rS100A4 (Fig. 3B). Overexpression of RAGE in HCT116/
RAGE cells alone resulted in elevated reporter activities of 
the MAPK/ERK and MAPK/JNK pathways as well as of 
the hypoxia signaling pathway. In addition, the stimulation 
of HCT116/RAGE cells with rS100A4 induced a 
significant hyperactivation of the MAPK/ERK and the 
hypoxia signaling pathways, but no further increase in the 
MAPK/JNK pathway reporter signals (Fig. 3B). Treatment 
of HCT116/vector cells with rS100A4 did not affect 
pathway activities significantly.
Next, we focused on the rS100A4‑induced 
activation of the MAPK/ERK signaling pathway in 
HCT116/RAGE cells. Treatment with rS100A4 increased 
the amount of phosphorylated ERK (p‑ERK) in these 
RAGE‑overexpressing cells, compared to the controls, 
thereby confirming the activation of MAPK/ERK 
pathway. Parallel incubation with rsRAGE reduced the 
phosphorylation of ERK, whereas the total amounts of 
Fig 3: S100A4-RAGE interaction hyperactivates MAPK/ERK and hypoxia signaling pathways. A) Relative luciferase 
activity of HCT116/vector cells, transfected with signaling pathway specific reporter constructs. Results were normalized to the internal 
control. Data represent mean values ± SD. B) Relative luciferase activity of HCT116/vector (grey bars) and HCT116/RAGE cells (black 
bars), transfected with signaling pathway specific reporter constructs. Cells were incubated for 24 h with BSA or rS100A4. Results were 
normalized to the respective untreated HCT116/vector cells. Data represent mean values ± SD.
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Fig 4: S100A4-RAGE interaction increases ERK phosphorylation and Hif1α protein level. A‑F) Increase in ERK 
phosphorylation by S100A4‑RAGE interaction. Western blot analysis of ERK phosphorylation in HCT116, HCT116/vector, and HCT116/
RAGE cells (A), in SW620, SW620/vector, and SW620/RAGE cells (C), and in DLD‑1, DLD‑1/vector, and DLD‑1/RAGE cells (C) 
after incubation for one hour with BSA (lanes 1,2,4), rS100A4 (lanes 3,5,6,7), additional treatment with rsRAGE (lane 6), or treatment 
with MEK inhibitor U0126 (lane 7). Membranes were incubated with antibodies against ERK, p-ERK, and β-actin. Intensities of p-ERK 
signals for each cell line (B,D,F, respectively) were quantified and normalized to its respective total ERK signals. G,H) Increase in Hif1α 
protein level. Western blot analysis of Hif1α in HCT116, HCT116/vector and HCT116/RAGE cells after incubation for 24 hours with BSA 
(G; lanes 1,2,4), rS100A4 (G; lanes 3,5,6), or additional treatment with rsRAGE (lane 6). Membranes were stained with antibodies against 
Hif1α and β-actin. Intensities of Hif1α protein signals were quantified and normalized to the respective β-actin signals (H).
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ERK remained unchanged (Fig. 4A,B). Preincubation of 
the cells with the MEK inhibitor U0126 resulted in only 
minimal residual ERK‑phoshorylation (Fig. 4A,B).
The increase in p‑ERK by treatment with 
extracellular rS100A4 was confirmed in other 
RAGE‑overexpressing CRC cells. Incubation with 
rS100A4 led to increased amounts of p‑ERK in SW620/
RAGE cells, but not in the control cell lines SW620 and 
SW620/vector (Fig. 4C,D). Simultaneous treatment with 
rsRAGE reduced p‑ERK levels in SW620/RAGE cells. 
Same observations were made for DLD‑1/RAGE cells, 
which did react with elevated p‑ERK levels to rS100A4 
incubation. Again, treatment with rsRAGE lowered the 
amount of p‑ERK. DLD‑1 and DLD‑1/vector cells were 
not affected by any kind of treatment (Fig. 4E,F).
Validation of the hypoxia signaling pathway 
activation upon rS100A4 incubation was performed by 
quantifying the amount of endogenous Hif1α protein, 
the major regulator of hypoxia response. Treatment of 
HCT116/RAGE cells with rS100A4 led to an increased 
protein level of Hif1α in cell lysates, that could be reduced 
by simultaneous treatment with rsRAGE (Fig. 4G,H). 
Neither RAGE‑overexpression alone not rS100A4 
incubation resulted in modulated Hif1α levels in the 
control cells.
RAGE expression in primary colorectal tumors 
correlates with patient survival
We examined the expression of RAGE in tumor 
samples of a cohort of 60 patients with CRC in stages 
Fig 5: RAGE expression in primary colorectal tumors correlates with patient survival. A‑C) RAGE (A) and S100A4 (B) mRNA 
expression is higher in primary CRCs, that metachronously develop distant metastases. RAGE mRNA expression is higher in S100A4 high 
expressing tumors (c; P=0.001). D‑I) Overall survival (D‑F) and metastasis‑free survival (G‑I) of CRC patients, based on RAGE (D,G), 
S100A4 (E,H) and combined RAGE and S100A4 (F,I) expression. RAGE as well as S100A4 mRNA expression levels were determined 
by qRT‑PCR in microdissected tumor cell populations of primary, not yet metastasized tumors of stages I, II and III. The cut‑off values to 
distinguish low and high expression levels were determined by ROC analyses.
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I, II, and III (without distant metastases at the day of 
tumor resection [23]) by gene-specific quantitative 
RT-PCR (Table 1). We first addressed the question on 
whether RAGE expression levels correlate with the 
development of metachronous metastases.
Metastases were more frequently formed in 
patients with high RAGE expression in their primary 
tumors (metachronously metastasized: RAGE mRNA 
expression/% calibrator, median 2.119) compared to those 
who did not metastasize in a follow‑up of 12 years (non‑
metastasized: RAGE mRNA expression/% calibrator; 
median 1.888) (Fig. 5A). Likewise, high S100A4 
expression also correlated to the metastases development 
(metastasized: S100A4 mRNA expression/% calibrator, 
median 3.715 vs. non‑metastasized: S100A4 mRNA 
expression/% calibrator, median 2.344) (Fig. 5B). 
Furthermore tumors with high S100A4 expression also 
expressed RAGE at high levels (P<0.001, Fig. 5C).
We then linked RAGE expression levels to patient 
survival using Kaplan‑Meier analysis. The cut‑off was 
determined by ROC analyses. We found a significant 
correlation of elevated RAGE expression with decreased 
overall survival (OS) (P=0.022; Fig. 5D) as well as 
decreased metastasis‑free survival (MFS) (P=0.021; 
Fig. 5G). The 5‑year OS was 87.2% (± 4.5%) for 
RAGE low‑expressers but 53.8% (± 13.8%) for patients 
with elevated RAGE expression in the tumor. High 
RAGE levels also correlated with shorter 5‑year MFS 
of 37.5% (± 12.1%) compared to 65.9% (± 7.1%) for 
RAGE low expressing patients.
Simultaneously, we determined the S100A4 
expression in the same samples. Elevated expression 
of S100A4 also showed a correlation with shorter OS 
(P=0.001; Fig. 5E) and with shorter MFS (P=0.018; 
Fig. 5H). Increased expression of S100A4 in tumors was 
also connected to shorter 5‑year OS (44.4% (± 16.6%) 
compared to 86.2% (± 4.8%) for S100A4 low expressers) 
and to shorter 5‑year MFS (41.2% (± 11.9%) compared 
to 65.1% (± 7.3%) for S100A4 low expressers).
By combining RAGE and S100A4, we also 
observed a significant decrease of the OS rate (P=0.004; 
Fig. 5F) and a strong reduction of the MFS rate when 
both markers genes were upregulated (P=0.058; Fig. 5I). 
However, the combination of RAGE and S100A4 did 
not improve the prognosis based on S100A4 exclusively. 
The 5‑year OS was 44.4% (± 16.6%) for patients with 
elevated RAGE and S100A4 expression in their tumors 
compared to 87.2% (± 4.9%) for patients with low 
expressions of both genes. Likewise, the 5‑year MFS 
was 37.5% (± 12.1%) when RAGE and S100A4 
were simultaneously highly expressed compared 
to 65.1% (± 7.3%) for patients with both gene expressed 
at low levels.
Taken together, RAGE was identified as biomarker 
for disease prognosis of CRC. Based on our findings 
on the importance of the S100A4‑RAGE interaction, 
therapeutic approaches targeting RAGE or intervening 
in RAGE dependent signaling early in tumor progression 
might represent alternative strategies restricting the 
S100A4‑induced metastasis in CRC.
DISCUSSION
Here we report the interaction of extracellular 
S100A4 and RAGE in CRC cells leading to 
hyperactivation of the MAPK/ERK and the hypoxia 
signaling pathway. An increase in cellular motility, after 
treatment with rS100A4, could be counteracted using 
RAGE‑antagonists. Analysis of primary colorectal tumors 
unveiled RAGE as a biomarker for prognosis of CRC. 
Elevated RAGE as well as S100A4 expression levels 
correlated significantly with shorter MFS and OS.
S100A4 expression in cancer affects many disease 
related cellular responses, like angiogenesis, cell motility, 
invasion, and cell survival, contributing to tumor 
progression and metastasis formation [3]. It is a target 
gene of T-cell factor/β-catenin transcription complex, 
which is often deregulated in CRC [6,24]. Clinical data 
acknowledged S100A4 as a prognostic biomarker for 
CRC metastasis [25]. The quantification of S100A4 
mRNA in plasma samples is suited as a diagnostic tool 
for CRC metastasis [26], which allows early therapeutic 
interventions to reduce S100A4 in tumor tissues, and in 
turn disease progression. One therapeutic aim is to target 
S100A4 gene expression within the tumor cells. In vivo 
application of small molecules as transcription inhibitor, or 
the systemic knock‑down of S100A4 expression by RNAi, 
were successful to reduce CRC metastasis [7,8,27,28]. 
Other studies evaluate the inhibition of S100A4 protein 
function with S100A4-specific antibodies, or by blocking 
its binding to RAGE with antagonistic peptides, shown 
for glioma and pancreatic cancer  [13, 29, 30]. For CRC, 
elevated RAGE expression in the intestine promotes tumor 
formation and disease progression [31,32]. However, the 
impact of RAGE expression on S100A4‑induced cell 
motility and metastasis formation in CRC has not been 
elucidated so far.
Here we demonstrate increased cellular motility 
by the stimulation of RAGE‑overexpressing CRC cells 
with rS100A4. This effect was reversed by inhibiting the 
S100A4‑RAGE interaction with simultaneous application 
of RAGE antagonists.
The interaction of S100A4 and RAGE has 
been shown first in human articular chondrocytes by 
immunoprecipitation [14], and was later classified as 
a direct interaction by biophysical characterization of 
receptor‑ligand binding [33]. In our study, we report 
the direct binding both proteins by precipitating RAGE 
with rS100A4, covalently bound to beads. We also 
provide data supporting the S100A4‑RAGE interplay, by 
measuring the release of sRAGE into the medium, after 
treatment with rS100A4. Raucci and colleagues describe 
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the release of soluble forms of RAGE upon ligand 
binding [22]. One mechanism involves alternative splicing 
of the RAGE transcript and the release of a C‑terminally 
altered RAGE [34]. In a different mechanism, the 
receptor is cleaved near the transmembrane region by 
metalloproteases, and the extracellular ligand binding site 
of the receptor is released from the cell surface [22]. In 
both mechanisms the increased amount of soluble RAGE 
fragments in the intercellular space can act as soluble 
decoy receptors by competing with binding of ligands.
By demonstrating the binding of S100A4 to RAGE 
and its effect on cellular motility of CRC cell lines, we 
were interested in the signaling pathways involved. 
When we analyzed a panel of cancer related signaling 
pathways in the cell line HCT116/RAGE, we found a 
significant increase in ERK as well as hypoxia pathway 
activity upon treatment with rS100A4. The activation of 
ERK signaling in CRC cells was previously described 
for other RAGE ligands besides S100A4; for AGEs in 
Caco‑2 [35], for S100P in SW480 [36], and for S100A8/
A9 in MC38 and Caco‑2 [31]. Interestingly, we already 
observed a minor increase in ERK‑signaling in DLD‑1/
RAGE cells without rS100A4 treatment. Since these 
cells are kept in DMEM containing higher glucose levels, 
RAGE activation might have partially occurred due to 
increased formation of AGEs in the medium. Other groups 
report RAGE‑independent ERK activation by extracellular 
S100A4 [37,38]. To the best of our knowledge, the 
modulation of ERK signaling in CRC cells upon S100A4‑
RAGE interaction has not been described before.
We also found an increase of the hypoxia signaling 
pathway in RAGE overexpressing cells, which was 
significantly enhanced by adding rS100A4. In general, an 
elevated Hif1α activity leads to cell type specific changes 
in gene expression of cell lines and cancer tissues [39]. 
For CRC, Hif1α was described to enhance resistance to 
apoptosis, increase cellular motility, and decrease response 
to chemotherapy [40–42]. A connection of RAGE and 
hypoxia response has been reported in breast and cervix 
carcinoma cell lines [43]. Hypoxic conditions in those 
cells induced the expression of RAGE and increased the 
RAGE‑dependent signaling, as well as cellular motility. 
Here, we observed an increase of a Hif1α-dependent 
reporter activity in RAGE‑overexpressing CRC cells, upon 
stimulation with rS100A4, verified by Western blotting. 
The elevated Hif1α protein level, caused by the incubation 
with rS100A4, was decreased when we interrupted the 
protein binding with rsRAGE or the RAGE-specific 
antibody.
In prostate cancer, recent mouse experiments 
revealed enhanced tumorigenesis of extracellular 
S100A4-RAGE interaction, by activating the NFκB 
signaling pathway [44]. In contrast, NFκB signaling has 
been shown to be constitutively active in most CRC cell 
lines [45]. We did not observe an increase in the NFκB 
pathway activity in our cells, neither by overexpressing 
RAGE nor by treatment with rS100A4. This is in line 
with a report by Boye and colleagues, demonstrating no 
increased NFκB pathway activation in CRC cell lines by 
applying rS100A4 [46]. Interestingly, in osteosarcoma 
cell lines, S100A4-mediated NFκB activation occurred 
independently of RAGE [46,47], indicating further 
receptors or receptor complexes interacting with S100A4. 
Taken together, the interaction of RAGE with rS100A4 
hyperactivates MAPK/ERK and hypoxia signaling 
pathways. Increased migration and invasiveness of CRC 
cells upon rS100A4 treatment was reversed by interfering 
with its binding to RAGE.
It has been shown, that RAGE is up‑regulated in the 
intestine as a result of chronic inflammation or diabetes, 
and leads to increased adenoma formation [32,48]. In 
CRC, elevated RAGE expression can form the basis for 
tumor formation and progression [49]. The switch to 
malignancy depends on the presence of RAGE ligands. 
The elevated expression and secretion of members of the 
S100 protein family into the tumor microenvironment 
drives the progression of the tumor and, eventually, 
metastasis formation [50], directly linked to patient 
survival. After determining the expression levels of 
RAGE and S100A4 in a panel of 60 human colorectal 
tumors, diagnosed and resected at stages I, II and III, 
we found a significant correlation of low overall and 
metastasis‑free survival with high RAGE expression as 
well as high S100A4 expression in the tumors. However, 
the combination of both RAGE and S100A4 expression 
did not improve the survival prognosis of the patients. 
Ligand binding of RAGE occurs in the extracellular tumor 
microenvironment, with ligands secreted either by the 
cancer cell itself, or by the surrounding tissue [51]. Thus, 
a tumor with high RAGE expression does not necessarily 
need high endogenous S100A4 expression levels to 
activate the receptor.
In summary, we demonstrated the importance of 
the interplay of S100A4 and RAGE for hyperactivation 
of ERK and hypoxia signaling, correlated with increased 
motility of CRC cells. Furthermore, high RAGE 
expression in primary CRC correlates with reduced 
metastasis‑free and overall survival of patients. Therefore, 
therapeutic approaches targeting RAGE or intervening in 
RAGE‑dependent signaling early in tumor progression 
might represent alternative strategies restricting the 
S100A4‑induced metastasis in CRC.
METHODS
Subjects and tissues
We obtained tissue specimens from 60 patients 
suffering from CRC with informed written consent 
(approved by Charité Ethics Committee, Charité 
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University Medicine, Berlin, Germany). All patients were 
staged I, II, or III (not distantly metastasized at the time 
point of surgery). They were previously untreated, did not 
develop tumors of a second entity, and showed no familial 
history of CRC. The patients’ tumors were surgically 
resected R0 (complete resection with no microscopic 
residual tumor). Twenty three patients formed distant 
metastases metachronously (after surgery), whereas 
37 patients remained free of metastases. A comprehensive 
description of the analyzed tissues can be found in [23]. 
Tumor specimens (all were adenocarcinomas) were snap 
frozen in liquid nitrogen. Serial consecutive cryosections 
were evaluated by a pathologist and tumor cell populations 
were microdissected.
Plasmid construction, cell culture, and 
transfection
The cDNA of human full length RAGE (OriGene) 
was cloned into pcDNA3.1 (Invitrogen), under the 
control of the CMV promoter, resulting in the plasmid 
pcDNA3.1/RAGE. Transfection of the cell lines HCT116, 
SW620 and DLD‑1 with pcDNA3.1/RAGE or the empty 
vector resulted in the cell lines HCT116/vector, HCT116/
RAGE, SW620/vector, SW620/RAGE, DLD‑1/vector, 
and DLD‑1/RAGE, respectively. All transfections were 
performed with Fugene HD (Promega), according to 
the manufacturer’s instructions. Transfected cells were 
selected with 1 mg/ml neomycin (PAA Laboratories). All 
cell lines derived from HCT116 and SW620 were grown 
in RPMI‑1640 medium, cell lines derived from DLD‑1 
were grown in DMEM (PAA Laboratories), each medium 
supplemented with 10% FCS (Invitrogen), in a humidified 
incubator at 37°C and 5% CO2. The cell lines were tested 
with the MycoAlert Mycoplasma Detection Kit (Lonza), 
and found to be free of mycoplasma. The genotype of the 
parental cell lines HCT116, SW620, and DLD‑1 were 
confirmed by short tandem repeat (STR) genotyping at the 
DSMZ (German Collection of Microorganisms and Cell 
Cultures; Braunschweig, Germany).
Real-time Quantitative Reverse Transcriptase 
Polymerase Chain Reaction (qRT-PCR)
Total RNA from cell culture or microdissected tumor 
tissues was isolated using the Universal RNA Purification 
Kit (Roboklon), according to the manufacturer’s 
instructions. Quantification of RNA concentration was 
performed with Nanodrop (Peqlab), and 50 ng total RNA 
was reversely transcribed with random hexamer primers 
in a reaction mix of 10 mM MgCl2, 1 × PCR‑buffer II, 
250 µM pooled dNTPs, 1 U/µL RNAse inhibitor, 2.5 U/
µL MuLV reverse transcriptase (Invitrogen). The 
reaction occurred at 42°C for 15 minutes, 95°C for 
5 minutes, and subsequent cooling at 4°C for 5 minutes. 
The cDNA product was amplified in a total volume 
of 10 µl in 96‑well plates using the LightCycler 480 
(Roche) and the following PCR conditions: 95°C 
for 10 minutes, followed by 45 cycles of 95°C for 
10 seconds, 60°C for 30 seconds, and 72°C for 4 seconds. 
For S100A4 cDNA quantification, the following 
primers and probes were used for a 124 bp amplicon: 
forward primer, 5′-gagctgcccagcttcttg-3′; reverse primer, 
5´-tgcaggacaggaagacacag-3´; fluorescein isothiocyanate 
(FITC) probe, 5′-tgatgagcaacttggacagcaaca-3′; and 
LCRed640-probe, 5′-gacaacgaggtggacttccaagagt-3′ [6]. 
For RAGE cDNA quantification, the following primers 
and probes were used to amplify a 226 bp fragment: 
forward primer, 5′-gtcggagctaatggtgac-3′; reverse primer, 
5´-ctgggcagggacttcac-3´; fluorescein isothiocyanate 
(FITC) probe, 5′-tggagccagaaggtggagcagta-3′; and 
LCRed640-probe, 5′-ctcctggtggaaccgtaaccct-3′. For 
cDNA quantification of the housekeeping gene glucose-
6‑phosphate dehydrogenase (G6PDH) the LightCycler‑
h‑G6PDH Housekeeping Gene Set (Roche) was used, 
according to manufacturer’s instructions, leading to a 
113 bp amplicon. Mean values were calculated from 
duplicate qRT‑PCR reactions. Each mean value of the 
expressed gene was normalized to the respective mean 
value of the housekeeping gene cDNA. The cDNA for the 
calibrator and the in‑run standard derived from HCT116 
cells was employed in serial dilutions simultaneously in 
each run.
Protein extraction and Western blot
For total protein extraction, cells were lysed 
with RIPA buffer (50 mM Tris‑HCl, 150 mM NaCl, 
1% Nonidet P‑40, supplemented with complete protease 
inhibitor tablets; Roche) for 30 minutes on ice. Protein 
concentration was quantified with Coomassie Plus 
(Bradford) Protein Assay Reagent (Pierce), according to 
manufacturer’s instructions, and lysates of equal protein 
concentration were separated with SDS‑PAGE and 
transferred to Hybond‑C Extra nitrocellulose membrane 
(GE Healthcare). Membranes were incubated in 
blocking solution containing 5% nonfat dry milk at room 
temperature. Incubation with the appropriate primary 
antibody was performed overnight at 4°C, followed by 
incubation with the respective HRP‑conjugated secondary 
antibody, diluted 1:10,000 in 5% BSA/TBST for 1 hour 
at room temperature. For RAGE detection we used the 
mouse anti‑human RAGE A11 antibody (1:1000; sc‑
80652, Santa Cruz Biotechnology), for GAPDH we 
used goat anti‑GAPDH V‑18 (1:500; sc‑20357, Santa 
Cruz Biotechnology). ERK was detected by rabbit 
anti‑p42/44 antibodies (1:1000; #9102, Cell Signaling) 
and phosphorylated ERK was detected by the rabbit anti‑
P‑p42/44 antibodies (1:1000; #9101, Cell Signaling). For 
Hif1α we used the rabbit anti-Hif1α antibody (1:1000; 
GTX127309P, GeneTex), and for β-actin we used the 
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mouse anti-β-actin AC-15 antibody (1:10,000; A1978, 
Sigma‑Aldrich). Antibody‑protein complexes were 
visualized with electrochemical‑luminescence reagent 
(100 mM Tris/HCl, 0.025% w/v luminol, 0.011% w/v 
para‑hydroxycoumaric acid, 10% v/v dimethylsulfoxide, 
0.004% v/v H2O2, pH 8.6) and subsequent exposure 
to CL‑XPosure™ Films (Pierce). Immunoblotting for 
GAPDH served as protein loading control. The signals 
were quantified with ImageJ version 1.74f [52]. All 
experiments were performed at least three independent 
times.
Immunocytochemistry
Cells were cultured on double‑chamber 
slides (Nunc) and were fixated for 15 minutes with 
0.04% glutaraldehyde. Endogenous peroxidase was 
inactivated for 20 minutes with 0.9% H2O2 and cells were 
permeabilized for 10 minutes with 0.5% Triton X100 
in 2.5% BSA. After blocking for 1 hour with 5% BSA, 
cells were incubated for 2 hours with the RAGE specific 
antibody (1:400; sc‑80652, Santa Cruz Biotechnology). 
Detection was performed using the biotin‑based ABC kit 
(Dako) with diaminobenzidine as substrate, according 
to manufacturer’s instructions. Positive signals resulted 
in brown staining. The slides were counterstained with 
haematoxylin and analyzed using a light microscope 
Axioplan2 (Leica) at a magnification of 40x. Negative 
control experiments were carried out by omitting the 
primary antibody.
RAGE pull-down
Dynabeads® (Antibody Coupling Kit 143.11D; 
Invitrogen), were coupled with recombinant human 
S100A4 (kind gift of K. Boye, Oslo; [46]) or BSA, 
respectively, according to the manufacturers’ protocol 
and finally blocked with 2% BSA in PBS. Three x 107 
HCT116/RAGE cells were lysed in RIPA buffer and 
incubated with 100 µl of coupled Dynabeads, with or 
without the presence of 25 µg RAGE H300 antibody 
(sc‑5563, Santa Cruz Biotechnology) overnight at 4°C. 
The beads were washed three times with PBS, subjected 
to SDS‑PAGE, and Western blotting was performed for 
detection of RAGE. The experiments were performed two 
times.
Treatment with recombinant human S100A4 or 
blocking substances
Cells were seeded into 6‑well plates up to 
70% confluency and were incubated overnight in growth 
medium, supplemented with 10% FCS. The medium was 
removed and replaced with growth medium containing 
0.5% FCS. The cells were either treated with rS100A4 
(R&D Systems) or, as control, with BSA. Counter 
treatment was performed with either purified human 
rsRAGE, or a purified RAGE-specific antibody (both 
described in [53]). The purity of the proteins used for 
treatment (rS100A4 and rsRAGE) was analysed via 
SDS‑PAGE and Coomassie staining (Fig. S1). The MEK 
inhibitor U0126 (#9903; Cell Signaling) was added to the 
cells at 10 µM, 1 hour before the treatment with rS100A4.
RAGE ELISA
The quantification of sRAGE in the medium 
of treated and untreated cells was performed with an 
ELISA Kit for human sRAGE (BioVendor) according to 
the manufacturers’ protocol. In brief, 5 x 105 HCT116, 
HCT116/vector, and HCT116/RAGE cells were treated 
for 24 hours with 5 µg/ml rS100A4 or, as control, with 
5 µg/ml BSA. The growth medium was removed and the 
concentration of sRAGE was measured. The experiment 
was repeated twice.
Boyden chamber transwell migration and 
invasion assay
The cell lines HCT116, SW620, and DLD‑1, and 
the respective clones, HCT116/vector, HCT116/RAGE, 
SW620/vector, SW620/RAGE, DLD‑1/vector and 
DLD‑1/RAGE, were used in cell migration and invasion 
analyses performed by Boyden chamber assays. Cells 
were treated for 24 hours with 5 µg/ml rS100A4 or, as 
control with 5 µg/ml BSA. The interaction of RAGE and 
S100A4 was blocked by adding either 30 µg/ml rsRAGE 
or 150 µg/ml purified RAGE antibody. For determining 
cell migration, 2.5 × 105 cells were seeded into each 
transwell chamber with filter membranes of 12 μm 
pore size (Millipore). For invasion, filter membranes 
were coated with Matrigel (BD Biosciences; diluted 1:3 
in growth medium) 4 hours before seeding 5 x 105 cells, 
and fresh medium was added to the bottom chamber. 
After 24 hours (migration) or 72 hours (invasion), 
respectively, inserts were removed and cells which had 
migrated through the membrane to the lower chamber 
were trypsinized and counted in a Neubauer chamber 
(LO‑Laboroptik). Each well was counted ten times. 
Each migration or invasion experiment was performed 
in duplicate. The average number of migrated or invaded 
cells was determined from at least three independent 
experiments.
Monitoring cell proliferation by MTT
Two x 103 cells of HCT116, HCT116/vector, 
HCT116/RAGE, SW620, SW620/vector, SW620/
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RAGE, DLD‑1, DLD‑1/vector and DLD‑1/RAGE 
cells were seeded in 96‑well plates (for each day one 
plate) and incubated for 24 hours to allow the cells 
to attach to the bottom of the wells. Determination of 
viable cells was performed by adding 3‑(4,5‑dimethyl‑
2‑thiazol)‑2,5‑diphenyl‑2H‑tetrazolium bromide (MTT; 
Sigma-Aldrich) to a final concentration of 0.5 mg/ml. After 
2 hours incubation at 37°C and 5% CO2 in a humidified 
incubator, the formazan crystals were resolved by 
10% SDS in 10 mM HCl and the absorption was measured 
at 560 nm. MTT measurements were performed daily for 
5 consecutive days, as triplicates in three independent 
experiments. The absorption data were used to calculate 
the doubling time of each cell line (V. Roth 2006; wwww.
doubling‑time.com). The growth rate of each cell line has 
been determined three times.
Signaling pathway analysis
The analysis of activated signaling pathways by 
ectopic RAGE expression, with or without treatment 
with rS100A4, was performed with the Cignal Finder 
Cancer 10‑pathway Reporter Luciferase Kit 
(SABiosciences), according to the manufacturers’ 
instructions. In brief, 2 x 104 cells were reversely 
transfected in the reporter plates and incubated over night 
at 37°C in a humidified incubator, followed by treatment 
with 5 µg/ml rS100A4 or 5 µg/ml BSA. Cells were lysed 
after 24 hours of incubation. The measuring of firefly 
luciferase and renilla luciferase activity was performed 
with an ‘infinity2000’ plate reader (Tecan), using StopGlo 
reaction mix (Promega). The pathway dependent reporter 
signal intensities of firefly luciferase were normalized to 
pathway independent renilla luciferase signal intensities. 
The experiment has been repeated twice.
Statistical analysis
Statistical analyses were performed with Sigma Stat 
Version 3.5. Comparison of more than two groups was 
performed by one‑way analysis of variance (ANOVA) 
and Bonferroni post hoc multiple comparison, or 
one‑way ANOVA on ranks and Tukey post hoc multiple 
comparison, if the normality test of the data failed. 
P values less than 0.05 were defined as statistically 
significant. Statistical evaluation of human CRC samples 
was performed using the non‑parametric two‑sided Mann‑
Whitney Rank Sum test. Survival rates were calculated 
with Kaplan‑Meier‑Estimator. The cut‑offs to distinguish 
low and high expression levels were determined using 
Reciever‑operator‑characteristics (ROC) analysis by 
taking the value with the highest Youden‑Index. All 
computations were made using IBM SPSS Statistics 21.
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